Business Context and Reporting Period
This Form 8-K is a current report filed by NanoVibronix, Inc. (trading symbol: NAOV) on October 19, 2022. The filing addresses a specific corporate event regarding the company's listing status on The Nasdaq Capital Market. Note: The request metadata references "Envue Medical, Inc.," but the source text explicitly identifies the registrant as NanoVibronix, Inc.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on regulatory compliance regarding stock listing requirements.
Material Changes
- Nasdaq Non-Compliance: The company was previously notified on September 2, 2022, of non-compliance with Nasdaq Listing Rule 5550(a)(2) due to a minimum bid price below $1.00 per share.
- Hearing Outcome: On October 17, 2022, the Nasdaq Hearings Panel granted the company a request for continued listing.
- Compliance Deadline: Continued listing is granted until December 15, 2022, contingent upon the company providing a written update to the Panel by that date.
Outlook, Risks, and Management Commentary
Management announced the hearing results via a press release on October 19, 2022. The primary risk identified is the potential loss of Nasdaq listing if the company fails to meet the minimum bid price requirement or provide the required update by the December 15, 2022 deadline. No forward-looking financial guidance or operational outlook is provided in this specific filing.
Investor Verification Checklist
- Verify the current trading price of NAOV to assess proximity to the $1.00 minimum bid requirement.
- Monitor for the company's written update to the Nasdaq Panel due on December 15, 2022.
- Review the attached press release (Exhibit 99.1) for additional details on the company's plan to regain compliance.
- Confirm the registrant name is NanoVibronix, Inc., not Envue Medical, Inc.